1435972-27-2Relevant academic research and scientific papers
Discovery of potent selective bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model. Part II: Optimization studies and demonstration of in vivo efficacy
Plummer, Mark S.,Cornicelli, Joseph,Roark, Howard,Skalitzky, Donald J.,Stankovic, Charles J.,Bove, Susan,Pandit, Jayvardhan,Goodman, Annise,Hicks, James,Shahripour, Aurash,Beidler, David,Lu, Xiao Kang,Sanchez, Brian,Whitehead, Christopher,Sarver, Ron,Braden, Timothy,Gowan, Richard,Shen, Xi Qiang,Welch, Katherine,Ogden, Adam,Sadagopan, Nalini,Baum, Heidi,Miller, Howard,Banotai, Craig,Spessard, Cindy,Lightle, Sandra
, p. 3443 - 3447 (2013/06/27)
Selective phosphodiesterase 2 (PDE2) inhibitors are shown to have efficacy in a rat model of osteoarthritis (OA) pain. We identified potent, selective PDE2 inhibitors by optimizing residual PDE2 activity in a series of phosphodiesterase 4 (PDE4) inhibitors, while minimizing PDE4 inhibitory activity. These newly designed PDE2 inhibitors bind to the PDE2 enzyme in a cGMP-like binding mode orthogonal to the cAMP-like binding mode found in PDE4. Extensive structure activity relationship studies ultimately led to identification of pyrazolodiazepinone, 22, which was >1000-fold selective for PDE2 over recombinant, full length PDEs 1B, 3A, 3B, 4A, 4B, 4C, 7A, 7B, 8A, 8B, 9, 10 and 11. Compound 22 also retained excellent PDE2 selectivity (241-fold to 419-fold) over the remaining recombinant, full length PDEs, 1A, 4D, 5, and 6. Compound 22 exhibited good pharmacokinetic properties and excellent oral bioavailability (F = 78%, rat). In an in vivo rat model of OA pain, compound 22 had significant analgesic activity 1 and 3 h after a single, 10 mg/kg, subcutaneous dose.
